Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, announces the addition of Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety.|
VetStem Biopharma proudly announces Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety.
June 13, 2016 --
VetStem Biopharma proudly announces Dr. Mark Hughes as the Senior Manager, Veterinary Clinical Research and Safety. Dr. Hughes, former Product Development Manager in R&D at Virbac Corporation, brings eight years of experience managing drug development projects through the process of pharmaceutical development, preclinical and clinical trials, and submissions to regulatory authorities for marketing approval in the US and Canada. Dr. Hughes received BS, MS, and DVM degrees from the University of California, Davis, and is licensed to practice in California. He also has provided commercial embryo transfer services for beef and dairy cattle, developed in-vitro diagnostics for diseases in animals and people, and managed a laboratory animal research facility.
“With 8 years of experience in the veterinary product development market and having extensive experience in clinical field trials Dr. Hughes will be a great addition to our team.” Dr. Robert Harman, CEO, explains. “Dr. Hughes will be responsible for the continued development of new services, products and clinical data generation. We believe with his previous history and understanding of the product development process, he will efficiently guide our projects through the FDA approval process.”
“I am very pleased to join the VetStem Biopharma team to be an integral part of a dynamic, industry-leading company in a field with breakthrough potential for treating a diverse range of diseases and injuries in companion animals and horses,” said Dr. Hughes. “I am excited to participate in the development of products that truly will benefit our animal friends worldwide.”
VetStem is currently in the product development phase for the first off-the-shelf stem cell product for the canine osteoarthritis. As many as two thirds of dogs over 7 years old are affected by osteoarthritis, which has created the largest existing market segment in pet therapeutics. Although currently marketed products can help decrease the crippling symptoms of osteoarthritis, they are not designed to regenerate and heal the damaged tissue that is causing pain. Regenerative medicine focuses on true regeneration of damaged tissues and organs.
< Back to Press Releases